Skip to main content

Doptelet FDA Approval History

Last updated by Judith Stewart, BPharm on Sep 7, 2020.

FDA Approved: Yes (First approved May 21, 2018)
Brand name: Doptelet
Generic name: avatrombopag
Dosage form: Tablets
Company: Dova Pharmaceuticals, Inc.
Treatment for: Thrombocytopenia, Idiopathic Thrombocytopenic Purpura

Doptelet (avatrombopag) is a second generation, orally administered thrombopoietin receptor agonist (TPO-RA) indicated for the treatment of:

  • Thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.
  • Thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

Development timeline for Doptelet

Jun 27, 2019Approval Dova Pharmaceuticals Announces FDA Approval of Doptelet (avatrombopag) for Treatment of Chronic Immune Thrombocytopenia (ITP)
May 21, 2018Approval FDA Approves Doptelet (avatrombopag) for Chronic Liver Disease Patients with Thrombocytopenia who are Undergoing a Medical Procedure
Nov 27, 2017Dova Pharmaceuticals Announces FDA Acceptance of the Avatrombopag New Drug Application (NDA) with Priority Review
Sep 22, 2017Dova Pharmaceuticals Announces New Drug Application Submission to FDA for Avatrombopag, a Second Generation Thrombopoietin Receptor Agonist

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.